Articles tagged with Drug Therapy
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
A Dartmouth study reveals that disruptions in the mTORC1 pathway can rescue neuronal overgrowth and synapse function dysregulated by Pten loss, potentially offering new treatments for autism spectrum disorders. The research team also found that administering Rapamycin to children showed some benefit to symptoms of autism.
A study found that living in a food desert increases the risk of heart attack, stroke, and early death for people with PAD. People with PAD living in food deserts were 17% more likely to experience a major cardiac event compared to those with better nutrition access.
The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
A Tel Aviv University study shows that pressure chamber therapy can improve social skills and reduce neuroinflammation in the autistic brain. The treatment, which involves high-pressure chambers with oxygen enrichment, was found to increase blood and oxygen supply to the brain, leading to improved brain function and social behavior.
The THERACAT project aims to deliver drugs only to tumor sites using bio-orthogonal catalysis, a promising approach for targeted cancer treatment. Researchers developed nanoparticles bearing metal catalysts to efficiently convert inactive pro-drugs into active drugs at the tumor site.
Researchers have developed a drug compound that stops cancer cell growth in mice with little effect on normal healthy cells, making it potentially nontoxic for patients. The therapy targets the epidermal growth factor receptor gene, which is overexpressed in about half of all triple-negative breast cancer cases.
The University of Missouri has earned an $8 million grant from the National Institutes of Health to expand its National Swine Resource and Research Center. The center will support research using genetically modified pigs to study human diseases, with a focus on therapies that can be translated from pig models to humans.
Studies on 18beta-glycyrrhetinic acid, human islet amyloid polypeptide (hIAPP), and fluoroquinolone derivatives explore new approaches to treating challenging diseases. Researchers aim to develop better therapeutics for liver diseases, which cause almost 2 million deaths worldwide every year.
A study of 43,000 veterans hospitalized with COVID-19 found that Black patients were less likely to receive systemic steroids, remdesivir, and immunomodulatory drugs. This racial disparity in care was attributed to within- and between-hospital differences.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
Researchers at KTH Royal Institute of Technology developed a method to track the growth of the HIV virus by highlighting its essential molecules. This breakthrough could lead to the creation of new therapies that target these molecules to prevent viral growth.
A comprehensive study reveals SARS-CoV-2 viral-to-human protein interaction network, showing how the virus hijacks human proteins. Researchers identified 23 candidate drugs, including an FDA-approved beta-blocker that shows promise in inhibiting viral infection.
Few studies utilize high-throughput screening (HTS) and high-content screening (HCS) techniques in anti-obesity drug discovery due to a lack of original data or experimental design information. This limits the development of effective pharmaceutical treatments for obesity-related diseases.
Researchers from McGill University developed a medical adhesive inspired by flatworms that uses suction to absorb blood and promote blood coagulation. The adhesive can be removed without causing re-bleeding, making it a potential replacement for wound sutures or delivering drugs.
Two promising neurokinin B antagonists, fezolinetant and elinzanetant, are being developed for the treatment of vasomotor symptoms, including hot flashes. Larger studies are necessary to confirm their benefits and risks. Hormone therapy remains the most effective treatment option for menopausal women.
A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
A Swedish cohort study found that direct oral anticoagulants (DOACs) were associated with a lower risk of kidney function decline or kidney failure compared to vitamin K antagonists (VKA). DOACs also showed a lower risk of acute kidney injury.
Researchers from the University of Cincinnati found that low levels of soluble amyloid-beta protein in the brain, rather than its buildup into plaques, are associated with cognitive decline and Alzheimer's disease. Patients with high levels of soluble amyloid-beta showed improved cognitive outcomes, contradicting previous theories.
The researchers will conduct multimodal imaging of 100 human vagus nerves using high-resolution technologies, providing unprecedented data on the vagus nerve's organization. This work aims to improve the safety and effectiveness of existing vagus nerve therapies, offering potential for novel neuromodulation therapies.
A new study found that fewer Asian, Black, and Hispanic patients qualify for anti-amyloid monoclonal antibody treatments, which may slow Alzheimer's progression. The treatment's effectiveness depends on the presence of amyloid plaques, with lower incidence in minorities.
A cross-sectional study of over 70,000 Asian Americans found significant variation in obesity prevalence among subgroups, with Filipino Americans having the highest rate at 28.7% and Chinese Americans the lowest at 13.2%. The study highlights the need for tailored strategies to address obesity disparities among Asian American populations.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
The Leducq Foundation has awarded $7.5 million to UVA researchers, led by Mete Civelek, to investigate sex differences in atherosclerosis and $8 million to Coleen McNamara to advance immunotherapy for cardiovascular disease. These projects aim to improve understanding of heart disease and develop new treatments.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
Researchers have discovered a drug candidate that can prevent lethal lung inflammation in mice by inhibiting PTP1B, a protein that accelerates neutrophil aging and reduces tissue damage. The treatment shows promise for treating acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
A phase 3 clinical trial showed tofersen reduces SOD1 and neurofilament light protein levels, slowing down disease progression. Longer-term use may help stabilize muscle strength and control in people with genetic ALS.
Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.
Neflamapimod, a p38α kinase inhibitor, demonstrates reversible neurodegeneration in animal models and improves clinical endpoints associated with cholinergic neuronal function in patients with dementia with Lewy bodies. The findings support the initiation of a confirmatory Phase 2b clinical trial for neflamapimod.
A randomized trial found that a 12-week online yoga program improved knee function in participants, but did not significantly reduce knee pain during walking. The study suggests that unsupervised online yoga programs can be feasible and improve physical function, but more research is needed to sustain the effectiveness.
A new study suggests that spironolactone, a medication for heart problems and high blood pressure, may also be effective in reducing alcohol drinking. The research found that increasing doses of spironolactone decreased alcohol consumption in mice and rats, as well as in humans with excessive alcohol drinking.
A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.
Researchers from Temple University Health System developed a device that significantly reduces blood clot size in pulmonary arteries, leading to improved heart function and shorter treatment duration. The breakthrough is based on data collected in the NIH-sponsored RESCUE trial.
A new genomic test can predict a patient's risk of developing severe COVID-19, according to research from the University of Virginia Health System. The test, called CovGENE, analyzes genes expressed in a person's blood to determine if they may experience a severe disease course with increased risk of death.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A team of scientists from Ural Federal University has developed a complex mathematical model to understand the dynamics of nanoparticles and viruses in cells. The model reveals how viruses cluster inside endosomes and interact with cellular proteins, shedding light on their behavior and replication mechanisms. This breakthrough can hel...
A newly developed agonistic antibody targeting TREM2 reduced amyloid burden and alleviated cognitive decline in mice with Alzheimer's disease. The study suggests that increasing TREM2 activation could have therapeutic effects such as improved cognition.
A study by Case Western Reserve University has identified a promising path to developing therapies for esophageal tumors. The research team linked the TGFβ-pathway, a cell signaling mechanism, to tumor development and found that a protein-coding gene called HNF4α is a predictive biomarker of cancer.
Researchers from Tokyo Metropolitan University have developed a method to directly measure the strength of skeletal muscle myotubes by analyzing wrinkles formed on an elastic substrate when stimulated with electric pulses. This new technique is more sensitive than existing measures and has great potential for accelerating drug discover...
Researchers identified critical period plasticity in the amygdala that can be treated with therapeutic intervention at key developmental time points. Early pharmacological intervention was shown effective in reducing fear-learning in the mouse model.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers found that brief rapamycin exposure in early adulthood can prevent age-related decline and extend lifespan. The study used fruit flies and mice to test the effects of short-term drug administration, showing protection against intestinal pathology and increased health span.
A large cross-sectional study found that baseline plasma antigen levels are highly associated with both the severity of pulmonary illness and clinically important patient outcomes in hospitalized COVID-19 patients. Higher antigen levels were linked to increased risk of pulmonary worsening and delayed hospital discharge.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.
A KAUST-led research team identified two drug treatments that boost the activity of molecules involved in cell adhesion, enhancing the ability of blood-forming stem cells to enter the bloodstream and produce new blood. This breakthrough could lead to improved bone marrow transplant success for leukemia patients.
The American College of Cardiology has published an expert consensus decision pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction. The guidance provides recommendations for individuals at high-risk and those with familial hypercholesterolemia, ...
A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
A national survey of US psychiatrists found discrepancies between their perceptions of certain psychoactive drugs' safety and therapeutic value and how they are categorized under the Controlled Substances Act. Psychiatrists rated psilocybin as having low misuse potential and high therapeutic potential, but it is a Schedule I drug with ...
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
A Rutgers scientist has developed a highly sensitive DNA test that can detect Lyme disease in horses, a condition that can cause long-term complications. The test, called genomic hybrid capture assay, was tested on a sick horse and successfully identified the pathogen, allowing for early diagnosis and treatment.
A proof-of-concept study developed three machine learning models to predict posttreatment recurrence in early-stage hepatocellular carcinoma patients. The models achieved high accuracy using imaging data alone, while combining clinical data did not significantly improve performance.
The study found a 31% decline in sleep medication use between 2013 and 2018, with the strongest decrease in FDA-approved medications. Behavioral treatments for insomnia are increasingly encouraged due to their effectiveness and reduced risk of adverse outcomes.
Intravenous (IV) nutrition is being used by professional athletes as a regular routine, despite lack of scientific evidence supporting its effectiveness and potential risks. The 'food first' approach is crucial to avoid normalization of unproven treatments.